Inotek Pharmaceuticals Corporation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Inotek Pharmaceuticals Corporation sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Inotek Pharmaceuticals Corporation: 7 sponsored US clinical trials, none currently recruiting.

Inotek Pharmaceuticals Corporation sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myocardial Infarction, with 1 trials.

Upper-quartile sponsor footprint

Inotek Pharmaceuticals Corporation sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 2

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
COMPLETED Phase 3

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
COMPLETED Phase 2

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
COMPLETED Phase 1

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
COMPLETED Phase 1

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
TERMINATED Phase 2

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167
COMPLETED Phase 2

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

NCT00271765

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Therapeutic Areas

Acute Myocardial Infarction 1
Ocular Hypertension 1
Glaucoma 1

How the Inotek Pharmaceuticals Corporation early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Acute Myocardial Infarction (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Inotek Pharmaceuticals Corporation: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Inotek Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Inotek Pharmaceuticals Corporation3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Inotek Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Inotek Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Inotek Pharmaceuticals Corporation page

7 registered trials is a research-attention snapshot, not an endorsement of Inotek Pharmaceuticals Corporation or any single study.

  • None of Inotek Pharmaceuticals Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acute Myocardial Infarction is the condition Inotek Pharmaceuticals Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myocardial Infarction trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Inotek Pharmaceuticals Corporation pipeline card: 7 registered trials from official public datasets.Report a data error.